|
1
|
Jemal A, Murray T, Ward E, et al: Cancer
statistics, 2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar
|
|
2
|
Friedel G, Pastorino U, Ginsberg RJ, et
al: Results of lung metastasectomy from breast cancer: prognostic
criteria on the basis of 467 cases of the International Registry of
Lung Metastases. Eur J Cardiothorac Surg. 22:335–344. 2002.
View Article : Google Scholar
|
|
3
|
Woessner JF Jr: Matrix metalloproteinases
and their inhibitors in connective tissue remodeling. FASEB J.
5:2145–2154. 1991.PubMed/NCBI
|
|
4
|
Nakajima M, Welch DR, Belloni PN and
Nicolson GL: Degradation of basement membrane type IV collagen and
lung subendothelial matrix by rat mammary adenocarcinoma cell
clones of differing metastatic potentials. Cancer Res.
47:4869–4876. 1987.PubMed/NCBI
|
|
5
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saito N, Hatori T, Murata N, et al: A
double three-step theory of brain metastasis in mice: the role of
the pia mater and matrix metalloproteinases. Neuropathol Appl
Neurobiol. 33:288–298. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Castellano G, Malaponte G, Mazzarino MC,
et al: Activation of the osteopontin/matrix metalloproteinase-9
pathway correlates with prostate cancer progression. Clin Cancer
Res. 14:7470–7480. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanayama H: Matrix metalloproteinases and
bladder cancer. J Med Invest. 48:31–43. 2001.PubMed/NCBI
|
|
9
|
Lin CW, Hou WC, Shen SC, et al: Quercetin
inhibition of tumor invasion via suppressing PKC
delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in
breast carcinoma cells. Carcinogenesis. 29:1807–1815. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee SO, Jeong YJ, Kim M, Kim CH and Lee
IS: Suppression of PMA-induced tumor cell invasion by capillarisin
via the inhibition of NF-kappaB-dependent MMP-9 expression. Biochem
Biophys Res Commun. 366:1019–1024. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Newton AC: Regulation of protein kinase C.
Curr Opin Cell Biol. 9:161–167. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zeigler ME, Chi Y, Schmidt T and Varani J:
Role of ERK and JNK pathways in regulating cell motility and matrix
metalloproteinase 9 production in growth factor-stimulated human
epidermal keratinocytes. J Cell Physiol. 180:271–284. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hozumi A, Nishimura Y, Nishiuma T, Kotani
Y and Yokoyama M: Induction of MMP-9 in normal human bronchial
epithelial cells by TNF-alpha via NF-kappa B-mediated pathway. Am J
Physiol Lung Cell Mol Physiol. 281:L1444–L1452. 2001.PubMed/NCBI
|
|
14
|
Weng CJ, Chau CF, Hsieh YS, Yang SF and
Yen GC: Lucidenic acid inhibits PMA-induced invasion of human
hepatoma cells through inactivating MAPK/ERK signal transduction
pathway and reducing binding activities of NF-kappaB and AP-1.
Carcinogenesis. 29:147–156. 2008. View Article : Google Scholar
|
|
15
|
Eberhardt W, Huwiler A, Beck KF, Walpen S
and Pfeilschifter J: Amplification of IL-1 beta-induced matrix
metalloproteinase-9 expression by superoxide in rat glomerular
mesangial cells is mediated by increased activities of NF-kappa B
and activating protein-1 and involves activation of the
mitogen-activated protein kinase pathways. J Immunol.
165:5788–5797. 2000.
|
|
16
|
Yao J, Xiong S, Klos K, et al: Multiple
signaling pathways involved in activation of matrix
metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast
cancer cells. Oncogene. 20:8066–8074. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Karin M: The regulation of AP-1 activity
by mitogen-activated protein kinases. J Biol Chem. 270:16483–16486.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Madrid LV, Mayo MW, Reuther JY and Baldwin
AS Jr: Akt stimulates the transactivation potential of the RelA/p65
subunit of NF-kappaB through utilization of the IkappaB kinase and
activation of the mitogen-activated protein kinase p38. J Biol
Chem. 276:18934–18940. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee JC, Lim KT and Jang YS: Identification
of Rhus verniciflua Stokes compounds that exhibit free
radical scavenging and anti-apoptotic properties. Biochim Biophys
Acta. 1570:181–191. 2002.
|
|
20
|
Jeon WK, Lee JH, Kim HK, et al:
Anti-platelet effects of bioactive compounds isolated from the bark
of Rhus verniciflua Stokes. J Ethnopharmacol. 106:62–69.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jung CH, Kim JH, Hong MH, et al:
Phenolic-rich fraction from Rhus verniciflua Stokes (RVS)
suppress inflammatory response via NF-kappaB and JNK pathway in
lipopolysaccharide-induced RAW 264.7 macrophages. J Ethnopharmacol.
110:490–497. 2007.
|
|
22
|
Park KY, Jung GO, Lee KT, et al:
Antimutagenic activity of flavonoids from the heartwood of Rhus
verniciflua. J Ethnopharmacol. 90:73–79. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song MY, Jeong GS, Kwon KB, et al:
Sulfuretin protects against cytokine-induced beta-cell damage and
prevents streptozotocin-induced diabetes. Exp Mol Med. 42:628–638.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chambers AF and Matrisian LM: Changing
views of the role of matrix metalloproteinases in metastasis. J
Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stetler-Stevenson WG, Hewitt R and
Corcoran M: Matrix metalloproteinases and tumor invasion: from
correlation and causality to the clinic. Semin Cancer Biol.
7:147–154. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Song MY, Jeong GS, Lee HS, et al:
Sulfuretin attenuates allergic airway inflammation in mice. Biochem
Biophys Res Commun. 400:83–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jang HS, Kook SH, Son YO, et al:
Flavonoids purified from Rhus verniciflua Stokes actively
inhibit cell growth and induce apoptosis in human osteosarcoma
cells. Biochim Biophys Acta. 1726:309–316. 2005.PubMed/NCBI
|
|
29
|
Jang DS, Park EJ, Hawthorne ME, et al:
Potential cancer chemopreventive constituents of the seeds of
Dipteryx odorata (tonka bean). J Nat Prod. 66:583–587. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee JC, Lee KY, Kim J, et al: Extract from
Rhus verniciflua Stokes is capable of inhibiting the growth
of human lymphoma cells. Food Chem Toxicol. 42:1383–1388. 2004.
|
|
31
|
Son YO, Lee KY, Lee JC, et al: Selective
antiproliferative and apoptotic effects of flavonoids purified from
Rhus verniciflua Stokes on normal versus transformed hepatic
cell lines. Toxicol Lett. 155:115–125. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ko JH, Lee SJ and Lim KT: 36 kDa
glycoprotein isolated from Rhus verniciflua Stokes fruit has
a protective activity to glucose/glucose oxidase-induced apoptosis
in NIH/3T3 cells. Toxicol In Vitro. 19:353–363. 2005.
|
|
33
|
Lim KT, Hu C and Kitts DD: Antioxidant
activity of a Rhus verniciflua Stokes ethanol extract. Food
Chem Toxicol. 39:229–237. 2001.
|
|
34
|
Choi J, Yoon BJ, Han YN, et al:
Antirheumatoid arthritis effect of Rhus verniciflua and of
the active component, sulfuretin. Planta Med. 69:899–904. 2003.
View Article : Google Scholar
|
|
35
|
Lee YR, Hwang JK, Koh HW, et al:
Sulfuretin, a major flavonoid isolated from Rhus
verniciflua, ameliorates experimental arthritis in mice. Life
Sci. 90:799–807. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chung TW, Moon SK, Chang YC, et al: Novel
and therapeutic effect of caffeic acid and caffeic acid phenyl
ester on hepatocarcinoma cells: complete regression of hepatoma
growth and metastasis by dual mechanism. FASEB J. 18:1670–1681.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar
|
|
38
|
Scorilas A, Karameris A, Arnogiannaki N,
et al: Overexpression of matrix-metalloproteinase-9 in human breast
cancer: a potential favourable indicator in node-negative patients.
Br J Cancer. 84:1488–1496. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cho HJ, Kang JH, Kwak JY, et al:
Ascofuranone suppresses PMA-mediated matrix metalloproteinase-9
gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent
mechanisms. Carcinogenesis. 28:1104–1110. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kajanne R, Miettinen P, Mehlem A, et al:
EGF-R regulates MMP function in fibroblasts through MAPK and AP-1
pathways. J Cell Physiol. 212:489–497. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Srivastava AK, Qin X, Wedhas N, et al:
Tumor necrosis factor-alpha augments matrix metalloproteinase-9
production in skeletal muscle cells through the activation of
transforming growth factor-beta-activated kinase 1 (TAK1)-dependent
signaling pathway. J Biol Chem. 282:35113–35124. 2007. View Article : Google Scholar
|
|
42
|
Frigo DE, Tang Y, Beckman BS, et al:
Mechanism of AP-1-mediated gene expression by select
organochlorines through the p38 MAPK pathway. Carcinogenesis.
25:249–261. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shaulian E and Karin M: AP-1 in cell
proliferation and survival. Oncogene. 20:2390–2400. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yokoo T and Kitamura M: Dual regulation of
IL-1 beta-mediated matrix metalloproteinase-9 expression in
mesangial cells by NF-kappa B and AP-1. Am J Physiol.
270:F123–F130. 1996.PubMed/NCBI
|
|
45
|
Lungu G, Covaleda L, Mendes O,
Martini-Stoica H and Stoica G: FGF-1-induced matrix
metalloproteinase-9 expression in breast cancer cells is mediated
by increased activities of NF-kappaB and activating protein-1. Mol
Carcinog. 47:424–435. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yamamoto Y and Gaynor RB: Therapeutic
potential of inhibition of the NF-kappaB pathway in the treatment
of inflammation and cancer. J Clin Invest. 107:135–142. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hong S, Park KK, Magae J, et al:
Ascochlorin inhibits matrix metalloproteinase-9 expression by
suppressing activator protein-1-mediated gene expression through
the ERK1/2 signaling pathway: inhibitory effects of ascochlorin on
the invasion of renal carcinoma cells. J Biol Chem.
280:25202–25209. 2005. View Article : Google Scholar
|
|
48
|
Ruhul Amin AR, Senga T, Oo ML, Thant AA
and Hamaguchi M: Secretion of matrix metalloproteinase-9 by the
proinflammatory cytokine, IL-1beta: a role for the dual signalling
pathways, Akt and Erk. Genes Cells. 8:515–523. 2003.PubMed/NCBI
|
